Enzolytics Inc (ENZC) Stock Continues to See Selling Pressure: Where is The Bottom?

There have been many small cap stocks which have made considerable gains this...

Stay Ahead of the
Stock Market Game!
Subscribe to Small Cap
Exclusive for more

trending

Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) is Attra...
Ardelyx Inc. (NASDAQ:ARDX) Is An In Demand Biotech
1globe Capital Llc. Picked Up Exelixis Inc. (NASDAQ:...

There have been many small cap stocks which have made considerable gains this year and one of the more notable ones in that regards is the Enzolytics Inc (OTCMKTS:ENZC) stock.

The Enzolytics stock was on the move yesterday and jumped by 13% to takes its gains over the course of the past week to as much as 25%. Although the gains made by the stock are certainly eye-catching, it is also necessary for investors to remember that the rally in the stock might be related to an announcement made by Enzolytics back on June 14. The company announced at the time that it has created definite plans by way of which it wants to take its ITV-1 anti-HIV therapy to clinical trials.

In addition to that, plans have also been made with regards to the distribution of the product in Europe. More importantly, the company also expects to generate considerable revenue from this product and hence, the excitement around the Enzolytics stock is perhaps understandable. In this regard, it should be pointed out that the product had been progressing towards a certification under the control of the Bulgarian Drug Agency.

Although that process was discontinued, it is necessary to note that there was considerable progress made and in addition to that, positive results had also emerged from clinical trials of patients. The positive results from the discontinued trial have given Enzolytics the confidence that the clinical trials it has planned under the control of the European Medicines Agency are going to be successful.

Stay in the lopp :

Hertz Global Holdings (HTZGQ) Stock is Back I...

Car rental company Hertz Global Holdings Inc (OTCMKTS:HTZGQ) was in considerable focus in the markets last week after the company announced that its

FinCanna Capital Corp. (CSE: CALI – OTCQB: FN...

FinCanna is one of the first royalty companies focused on licensed medical marijuana in the U.S., and represents a smarter investment opportunity. The company combines

Advantis Corporation (OTCMKTS:ADVT) Rolls Out...
Advantis Corporation (OTCMKTS:ADVT) shares rose 13.56% to $0.0335 and were flat in after-hours trading. Share prices have been trading in a 52-week range of

related post

Skip to content